Carlo Sala Frigerio1, Pierre Lau, Evgenia Salta, Jos Tournoy, Koen Bossers, Rik Vandenberghe, Anders Wallin, Maria Bjerke, Henrik Zetterberg, Kaj Blennow, Bart De Strooper. 1. From the VIB Center for the Biology of Disease (C.S.F., P.L., E.S., B.D.S.), Leuven; Center for Human Genetics and LIND (C.S.F., P.L., E.S., B.D.S.), and Alzheimer Research Centre KU Leuven, Leuven Institute for Neuroscience and Disease (R.V.), University of Leuven; Geriatric Medicine (J.T.), and Neurology Department (R.V.), University Hospitals Leuven; Department of Clinical and Experimental Medicine and LIND (J.T.), Laboratory for Cognitive Neurology, Department of Neurosciences (R.V.), KU Leuven, Belgium; Netherlands Institute for Neuroscience (K.B.), Amsterdam, the Netherlands; Clinical Neurochemistry Laboratory (A.W., M.B., H.Z., K.B.), Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), Queen Square, London, UK.
Abstract
OBJECTIVE: We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease (AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia and nonaffected control subjects. METHODS: Using quantitative PCR, we profiled the expression level of 728 miRNAs in CSF of nonaffected control subjects and patients with clinically ascertained AD dementia, and we further compared the expression level of candidate miRNAs in 37 control subjects and 35 patients with AD dementia. RESULTS: The level of hsa-miR-27a-3p in CSF is reduced in patients with dementia due to AD in 2 different cohorts of subjects (cohort 1: p = 0.008; cohort 2: p = 0.015; 2-tailed unpaired Welch t test). Moreover, low levels of hsa-miR-27a-3p were accompanied by high CSF tau levels and low CSF β-amyloid levels. CONCLUSIONS: Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
OBJECTIVE: We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease (AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia and nonaffected control subjects. METHODS: Using quantitative PCR, we profiled the expression level of 728 miRNAs in CSF of nonaffected control subjects and patients with clinically ascertained AD dementia, and we further compared the expression level of candidate miRNAs in 37 control subjects and 35 patients with AD dementia. RESULTS: The level of hsa-miR-27a-3p in CSF is reduced in patients with dementia due to AD in 2 different cohorts of subjects (cohort 1: p = 0.008; cohort 2: p = 0.015; 2-tailed unpaired Welch t test). Moreover, low levels of hsa-miR-27a-3p were accompanied by high CSFtau levels and low CSF β-amyloid levels. CONCLUSIONS: Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
Authors: Adrià Dangla-Valls; José Luis Molinuevo; Jordi Altirriba; Raquel Sánchez-Valle; Daniel Alcolea; Juan Fortea; Lorena Rami; Mircea Balasa; Cristina Muñoz-García; Mario Ezquerra; Rubén Fernández-Santiago; Alberto Lleó; Albert Lladó; Anna Antonell Journal: Mol Neurobiol Date: 2016-10-13 Impact factor: 5.590
Authors: L Cheng; J D Doecke; R A Sharples; V L Villemagne; C J Fowler; A Rembach; R N Martins; C C Rowe; S L Macaulay; C L Masters; A F Hill Journal: Mol Psychiatry Date: 2014-10-28 Impact factor: 15.992